QNRX: Quoin Pharmaceuticals Ltd Company Short-Term Debt

Quoin Pharmaceuticals (QNRX) operates by developing therapies for rare skin pathologies, the demand for which remains insulated from market cycles and GDP fluctuations. The current development stage relies on the utilization of existing reserves to conduct clinical trials, with the metric standing at 0.00. The price action of the securities on the GURU.Markets platform reflects the impact of partnerships with global suppliers, which are accelerating the commercialization of innovative gels.

Liquidity control is critical for Quoin Pharmaceuticals (QNRX), as its success depends on regulatory approvals for rare skin pathology therapies rather than GDP cycles. The dynamics of short-term financial liabilities reflect the total obligations maturing within one year, where a downward trend confirms solvency, while a sharp increase signals a risk of capital shortages during the R&D phase.